Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial.

PLoS One 2008 May 14;3(5):e2158. Epub 2008 May 14.

Department of Neurology, Charité Universitaetsmedizin Berlin, Berlin, Germany.

Background: Pneumonia is a major risk factor of death after acute stroke. In a mouse model, preventive antibacterial therapy with moxifloxacin not only prevents the development of post-stroke infections, it also reduces mortality, and improves neurological outcome significantly. In this study we investigate whether this approach is effective in stroke patients.

Methods: Preventive ANtibacterial THERapy in acute Ischemic Stroke (PANTHERIS) is a randomized, double-blind, placebo-controlled trial in 80 patients with severe, non-lacunar, ischemic stroke (NIHSS>11) in the middle cerebral artery (MCA) territory. Patients received either intravenous moxifloxacin (400 mg daily) or placebo for 5 days starting within 36 hours after stroke onset. Primary endpoint was infection within 11 days. Secondary endpoints included neurological outcome, survival, development of stroke-induced immunodepression, and induction of bacterial resistance.

Findings: On intention-to treat analysis (79 patients), the infection rate at day 11 in the moxifloxacin treated group was 15.4% compared to 32.5% in the placebo treated group (p = 0.114). On per protocol analysis (n = 66), moxifloxacin significantly reduced infection rate from 41.9% to 17.1% (p = 0.032). Stroke associated infections were associated with a lower survival rate. In this study, neurological outcome and survival were not significantly influenced by treatment with moxifloxacin. Frequency of fluoroquinolone resistance in both treatment groups did not differ. On logistic regression analysis, treatment arm as well as the interaction between treatment arm and monocytic HLA-DR expression (a marker for immunodepression) at day 1 after stroke onset was independently and highly predictive for post-stroke infections.

Interpretation: PANTHERIS suggests that preventive administration of moxifloxacin is superior in reducing infections after severe non-lacunar ischemic stroke compared to placebo. In addition, the results emphasize the pivotal role of immunodepression in developing post-stroke infections.

Trial Registration: Controlled-Trials.com ISRCTN74386719.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002158PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2373885PMC
May 2008
15 Reads

Publication Analysis

Top Keywords

ischemic stroke
16
antibacterial therapy
12
neurological outcome
12
preventive antibacterial
12
stroke
9
non-lacunar ischemic
8
infection rate
8
treatment arm
8
outcome survival
8
treated group
8
severe non-lacunar
8
acute ischemic
8
therapy acute
8
stroke onset
8
moxifloxacin
6
protocol analysis
4
0114 protocol
4
group 0114
4
analysis moxifloxacin
4
325% placebo
4

References

(Supplied by CrossRef)
Complications after acute stroke.
RJ Davenport et al.
Stroke 1996
Early predictors of death and disability after acute cerebral ischemic event.
H Henon et al.
Stroke 1995; 1995
Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group.
PU Heuschmann et al.
Arch Intern Med 2004; 2004

Similar Publications